Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 7936 AL 7950

Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer's Treatment

Fatima R, Khan Y, Maqbool M, Ramalingam PS, Khan MG, Bisht AS, Hussain MS.

Curr Protein Pept Sci. 2025;26(7):515-545. doi: 10.2174/0113892037362037250205143911.

Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies

La Joie R, Cummings JL, Dage JL, Galasko D, Ikonomovic MD, Karikari TK, Landau SM, Llibre-Guerra JJ, Mummery CJ, Ossenkoppele R, Price JC, Risacher SL, Smith R, van Dyck CH, Carrillo MC.

Alzheimers Dement. 2025 Nov;21(11):e70997. doi: 10.1002/alz.70997.

Is the Era of One-Size-Fits-All Alzheimer's Treatment Officially Over?

Verma S, Kumari K, Kesharwani P, Verma K, Dwivedi J, Paliwal S, Sharma S.

J Mol Neurosci. 2025 Dec 22;76(1):3. doi: 10.1007/s12031-025-02445-1.

Diverse role of S100 calcium-binding protein B in alzheimer's disease: pathological mechanisms and therapeutic implications

Sarkar S, Porel P, Kosey S, Aran KR.

Inflammopharmacology. 2025 Apr;33(4):1803-1816. doi: 10.1007/s10787-025-01697-y. Epub 2025 Mar 9.

Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease

Grill JD, Tam S, Thai G, Vides B, Pierce AL, Green K, Gillen DL, Teng E, Kremen S, Beigi M, Rissman RA, Léger GC, Balasubramanian A, Revta C, Morrison R, Jennings R, Pa J, Zhang J, Jin S, Messer K, Feldman HH.

Neurology. 2025 Jan 14;104(1):e210152. doi: 10.1212/WNL.0000000000210152. Epub 2024 Dec 13.

Towards a better diagnosis and treatment of dementia: Identifying common and distinct neuropathological mechanisms in Alzheimer's and vascular dementia

Vollhardt A, Frölich L, Stockbauer AC, Danek A, Schmitz C, Wahl AS.

Neurobiol Dis. 2025 May;208:106845. doi: 10.1016/j.nbd.2025.106845. Epub 2025 Feb 24.

A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD

Erichsen JM, Register TC, Sutphen C, Ma D, Gaussoin SA, Rudolph M, Rundle M, Bateman JT, Lockhart SN, Sai KKS, Whitlow C, Craft S.

Alzheimers Dement. 2025 Oct;21(10):e70704. doi: 10.1002/alz.70704.

Unraveling the Role of Autotaxin and Lysophosphatidic Acid in Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Potential

García-de Soto J, Castro-Mosquera M, Pouso-Diz JM, Fernández-Cabrera A, Rodríguez-Arrizabalaga M, Debasa-Mouce M, Camino-Castiñeiras J, Minguillón Pereiro AM, Aramburu-Núñez M, Romaus-Sanjurjo D, Aldrey JM, Pego-Reigosa R, Pías-Peleteiro JM, Sobrino T, Ouro A.

Int J Mol Sci. 2025 Jul 23;26(15):7068. doi: 10.3390/ijms26157068.

Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease

Pokrzyk J, Kulczyńska-Przybik A, Guzik-Makaruk E, Winkel I, Mroczko B.

Int J Mol Sci. 2025 Feb 24;26(5):1935. doi: 10.3390/ijms26051935.

Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer's disease

Panza F, Dibello V, Sardone R, Zupo R, Castellana F, Leccisotti I, Moretti MC, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Resta E, Lozupone M.

Expert Opin Biol Ther. 2025 Mar;25(3):275-283. doi: 10.1080/14712598.2025.2463963. Epub 2025 Feb 7.

Unmasking a Paradox: Roles of the PD-1/PD-L1 Axis in Alzheimer's Disease-Associated Neuroinflammation

Moadab A, Khorramdelazad H, Javar MTA, Nejad MSM, Mirzaie S, Hatami S, Mahdavi N, Ghaffari S, Yazdian FA.

J Neuroimmune Pharmacol. 2025 Apr 26;20(1):46. doi: 10.1007/s11481-025-10206-5.

Exosomes in Alzheimer's disease: From pathogenesis to therapeutics-A comprehensive review of diagnostic and drug delivery applications

Shahlaei M, Afkhami H, Ahmadieh-Yazdi A, Mirmazloumi SH, Sahraei SS, Akbari M, Yang P, Manoochehri H, Tanzadehpanah H, Mahaki H, Sundararaman A, Mohan S, Sheykhhasan M, Al-Musawi S, Dama P.

Biomed Pharmacother. 2025 Nov;192:118548. doi: 10.1016/j.biopha.2025.118548. Epub 2025 Sep 22.

Targeting Transferrin Receptor 1 for Enhancing Drug Delivery Through the Blood-Brain Barrier for Alzheimer's Disease

Shen X, Li H, Zhang B, Li Y, Zhu Z.

Int J Mol Sci. 2025 Oct 8;26(19):9793. doi: 10.3390/ijms26199793.

Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions

Knopman DS.

Alzheimers Dement. 2025 Jan;21(1):e14043. doi: 10.1002/alz.14043. Epub 2024 Dec 24.

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease

Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ.

J Prev Alzheimers Dis. 2025 Nov;12(9):100337. doi: 10.1016/j.tjpad.2025.100337. Epub 2025 Sep 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias